Skip to content

The efficacy of Memantine combined with Speech language therapy for post stroke non-fluent aphasia rehabilitation

The efficacy of Memantine combined with Speech language therapy for post stroke non-fluent aphasia rehabilitation

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400085793
Enrollment
Unknown
Registered
2024-06-18
Start date
2017-11-10
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post stroke aphasia

Interventions

SLT group:Only receive SLT treatment
Memantine+SLT group:Receive memantine + SLT

Sponsors

Beijing Boai Hospital, China Rehabilitation Research Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria were: (1) age between 18 and 70 years, (2) unilateral cortical-subcortical or subcortical lesions caused by a single infarction or hemorrhage diagnosed as stroke by CT/MRI, (3) aphasia diagnosis according to the Western Aphasia Battery (WAB), Fluency =6 was classified as non-fluency aphasia. (4) presence of aphasia for 4 weeks to 6 months prior to the Screening visit, (5) Patients and caregivers are given written informed consent to participate in this trial. (6) Native Chinese (7) Right handedness (8) Junior high school education or above (9) Clear awareness and ability to cooperate with treatment (10) Patient and agent have signed informed consent form.

Exclusion criteria

Exclusion criteria: Exclusion criteria were: (1) Presence of a severe language deficit, (2) history of any other neurological or psychiatric disease impairing language and communicative ability, (3) severe visual agnosia,(4) severe limb apraxia and severe speech apraxia , (5) severe depression,(6) epilepsy,(7) pregnancy, (8) recent myocardial infarction, (9) uncompensated congestive heart failure, (10) uncontrolled hypertension, (11) hypersensitivity toward memantine, (12) ongoing medication with agents interfering with memantine (including amantadine, dextromethorphan, or ketamine).Any concomitant medication was kept unchanged during the study.

Design outcomes

Primary

MeasureTime frame
WAB-AQ;

Secondary

MeasureTime frame
MMSE;Spontaneous speech -AQ;Auditory comprehension -AQ;Repeating -AQ;Naming -AQ;

Countries

CHINA

Contacts

Public ContactLuping Song

Beijing Boai Hospital, China Rehabilitation Research Center

SongLuping882002@aliyun.com+86 136 8138 8763

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026